Celyad SA should be added to the growing list of companies active in developing chimeric antigen receptor T-cell (CAR-T) therapies, following the acquisition of a portfolio of preclinical CAR-T product candidates from Lebanon, N.H.-based Celdara Medical’s OnCyte oncology division.
The acquisition, announced Jan. 6 and valued at more than $100 million plus sales milestones [See Deal], comes just a day after another CAR-T pioneer, Kite Pharma...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?